CI-980 in advanced melanoma and hormone refractory prostate cancer

Invest New Drugs. 2000 May;18(2):187-91. doi: 10.1023/a:1006382014403.

Abstract

Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines.

Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks.

Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively.

Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carbamates / adverse effects
  • Carbamates / therapeutic use*
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Pyrazines / adverse effects
  • Pyrazines / therapeutic use*
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Carbamates
  • Pyrazines
  • Pyridines
  • canertinib dihydrochloride